Frontlight ResearchEarly access
Taking people in United StatesPhase 2
Guanfacine for Alcohol Use Disorder (AUD)
Key facts
- Who runs it
- Indiana University
- Where
- Indianapolis and Newark, United StatesSee the 2 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 200 people, planned
- Started
- 3 Oct 2025
- Expected to end
- 7 Sept 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Guanfacine Extended Release (XR)
- Placebo
- Record updated
- 11 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- be assigned as a biological male or female at birth and identify as such
- meet current Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM V) criteria for moderate to severe AUD
- be ≥18 years old and have a body mass index (BMI) of 18-35
- express a desire to quit alcohol as determined by the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES)
- demonstrate a positive urine for alcohol on admission to study procedures
- be able to provide informed verbal and written consent
- be able to read English and complete study evaluations
- be in good health as verified by the intake 1 physical examination
Who cannot take part
- regular use of medications in the last 6 months that, in the opinion of the site physician may be contraindicated with GXR and be potentially harmful to the participant
- meet criteria for moderate to severe Substance Use Disorder (SUD), excluding alcohol and nicotine
- have cardiovascular disease including high blood pressure,
- have bradycardia with a sitting heart rate (HR) of <60 bpm
- show EKG evidence of any clinically significant conduction abnormalities, including a Bazett's corrected QT interval (QTc) >470 msec for women and QTc>450 msec for men
- have a positive screen for substances of abuse, excluding alcohol, nicotine,
- being psychotic or otherwise severely psychiatrically disabled (including suicidal, homicidal, current mania)
- meet criteria for physiological dependence on alcohol requiring medical detoxification
- be pregnant or breast feeding
- be using monophasic contraceptives
- be hypotensive with sitting blood pressure below 100/50 mmHG
This trial is currently available in United States.
- The Stark Neuroscience Building (Goodman Hall)Indianapolis, United StatesContact: Helen C Fox, PhDTaking people
- Rutgers School of Health ProfessionalsNewark, United StatesContact: Suchismita Ray, PhDTaking people
About the trial
What the trial wants to find out
The investigators assess whether guanfacine extended release (GXR; 3mg/d) compared with placebo (PBO) will attenuate drinking and drinking-related factors in N=200 men and women with Alcohol Use Disorder (AUD) across 12-weeks.
The 2 groups in the trial
- Guanfacine Extended Release (XR)Treatment being tested
Participants receive guanfacine XR, 3mg tablet orally, once per day for 12 weeks
- PlaceboPlacebo, for comparison
Participants receive guanfacine XR, placebo tablet orally, once per day for 12 weeks
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Guanfacine for Alcohol Use Disorder (AUD): a Telehealth Approach
- Record updated
- 11 May 2026